Clinical trial · Interventional
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of Endometrium | Endometrial Adenocarcinoma | ALIAS | 0.90 |
| Cervical Carcinoma | Cervical Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Cutaneous Melanoma | Cutaneous Melanoma | ONTOLOGY_EXACT | 0.98 |
| Nonseminomatous Germ Cell Tumor | — | UNRESOLVED | — |
| Prostate Adenocarcinoma | Prostate Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Renal Cancer | — | UNRESOLVED | — |
| Seminomatous Germ Cell Tumor | — | UNRESOLVED | — |
| Soft Tissue Sarcoma (STS) | Soft Tissue Sarcoma | ONTOLOGY_EXACT |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with metastatic cancer
- description
- * Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients: * Cohort 1 : urothelial carcinoma * Cohort 2 : renal carcinoma * Cohort 3 : prostate adenocarcinoma * Cohort 4 : upper aerodigestive tract carcinoma * Cohort 5 : cervical carcinoma * Cohort 6 : adenocarcinoma of endometrium * Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients: * Cohort 7 : cutaneous melanoma * Cohort 8 : soft tissue sarcoma * Cohort 9 : seminomatous and nonseminomatous germ cell tumors
- interventionNames
- Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
Primary outcomes (1)
- measure
- Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor)
- timeFrame
- 1 year after the Last Patient Last Visit
- description
- It is defined as the ratio of number of patients for whom DP cells were detected (by at least 1 of the 2 techniques) by the total number of patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors * 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet * 3\. Age ≥ 18 years * 4\. Patient affiliated to a French Social Security scheme * 5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study. Exclusion Criteria: * 1\. Patient with localized disease. * 2\. Pregnant or breast-feeding women. * 3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol. * 4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
References
Publications (0)
Data not yet available